• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Chris Newmarker

BD stock up on Street-beating preliminary quarterly revenue numbers

January 12, 2021 By Chris Newmarker

BD-logo-new

Becton Dickinson (NYSE:BDX) today announced that it brought in $5.3 billion in revenue for its first quarter ended Dec. 31, 2020, beating the nearly $4.7 billion expected by Wall Street analysts. The announcement of the preliminary unaudited Q1 results sent BDX shares up 1.8% to $261.75 apiece by midday trading today. MassDevice’s MedTech 100 Index, which includes […]

Filed Under: Business/Financial News, Featured Tagged With: BD, Becton Dickinson

BREAKING: BD orders for COVID-19 vaccine injection devices surpass 1 billion

December 16, 2020 By Chris Newmarker

BD logo

Becton Dickinson (NYSE:BDX) announced today that orders have surpassed 1 billion for syringes and needles needed to deliver COVID-19 vaccines. The Franklin Lakes, N.J.–based medtech giant now has commitments from governments in countries including the United States, Australia, Belgium, Canada, Germany, Netherlands, Saudi Arabia, Spain and the United Kingdom. BD has already delivered more than 300 […]

Filed Under: Drug-Device Combinations, Featured Tagged With: BD, coronavirus, COVID-19, syringes

BD is playing a crucial role delivering COVID-19 vaccines: Here’s how

December 15, 2020 By Chris Newmarker

BD needles syringes

Hundreds of millions of vaccine doses will require hundreds of millions of syringes from companies such as BD. As much-hoped-for COVID-19 vaccines roll out to the public, Becton Dickinson (NYSE:BDX) faces an arguably impressive challenge: The Franklin Lakes, N.J.–based medtech giant already has commitments to provide more than 800 million needles and syringes to deliver future COVID-19 […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured Tagged With: BD, coronavirus, COVID-19, syringes

Canada approves Tandem Diabetes Caree’s advanced hybrid closed-loop insulin pump

November 23, 2020 By Chris Newmarker

Tandem Diabetes Care

Tandem Diabetes Care (NSDQ:TNDM) announced today that Health Canada has approved its t:slim X2 insulin pump with Control-IQ technology. The news comes nearly a year after the U.S. launch of the t:slim X2 with Control-IQ. All in-warranty t:slim X2 pump users in Canada will be able to add Control-IQ technology to their existing pump via a […]

Filed Under: Diabetes, Featured Tagged With: Health Canada, insulin, Tandem Diabetes Care

Alaris remediation could cost BD up to $244M

November 18, 2020 By Chris Newmarker

BD-logo-new

Becton Dickinson (NYSE:BDX) in its most recent fiscal year set aside $244 million to cover future product remediation costs, including the company’s work to fix its problematic Alaris infusion pumps. The Franklin Lakes, N.J.–based company has had shipments of the pumps on hold since early this year, when FDA called for a comprehensive 510(k) submission to […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Recalls Tagged With: BD, Becton Dickinson

Qosina offering SmartSite swabbable needle-free injection sites

November 3, 2020 By Chris Newmarker

Qosina SmartSite swabbable needle-free injection sites

Qosina (Ronkonkoma, N.Y.) is touting the variety of SmartSite swabbable needle-free injection sites that it offers. The needle-free injection sites feature an ergonomic design and a smooth, flat top that can be easily disinfected, according to Qosina. Said the company: ” These components are equipped with a valve, that when activated, forms an airtight seal […]

Filed Under: Uncategorized Tagged With: Qosina

Baxter has a serious infusion pump recall

October 29, 2020 By Chris Newmarker

Baxter

Baxter (NYSE:BAX) has issued an urgent device correction involving hundreds of thousands of Sigma Spectrum infusion pumps in which it warns that improper cleaning could cause corrosion around the batteries. So far, Baxter has received 16 reports of serious injuries related to the problem. FDA has labeled the recall as Class I, its most serious level. […]

Filed Under: Featured, Food & Drug Administration (FDA), Recalls Tagged With: Baxter, infusion systems

HHS gives Vaxxas $22M to support vaccine patch tech

October 5, 2020 By Chris Newmarker

Vaxxas micropatch vaccine COVID-19

Vaxxas announced today that it has received a $22 million award from the Biomedical Advanced Research and Development Authority (BARDA) at U.S. HHS to support a clinical study involving the company’s vaccine-delivery patch. The money will mostly pay for a Phase 1 clinical study in which Vaxxas’ high-density micro-array patch (HD-MAP) delivering pandemic influenza vaccine […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup Tagged With: BARDA, coronavirus, COVID-19, HHS, Merck, Vaxxas

Abbott’s FreeStyle Libre 3 receives CE Mark

September 28, 2020 By Chris Newmarker

Abbott FreeStyle Libre 3 sensor pennies CGM diabetes

Abbott (NYSE:ABT) has won the CE Mark in the European Union for its next-generation FreeStyle Libre 3 continuous glucose monitoring system. Officials at Abbott boast that the Libre 3 technology includes a super small, thin sensor. It’s the size of two U.S. pennies stacked together and able to accurately provide real-time glucose readings over 14 days […]

Filed Under: Business/Financial News, Diabetes, Diagnostics, Featured, Regulatory/Compliance Tagged With: abbott, Abbott Laboratories

Could Vaxxas’ tiny patches enable a better COVID-19 vaccine?

September 2, 2020 By Chris Newmarker

Vaxxas micropatch vaccine COVID-19

Tiny vaccine delivery patches could solve logistical challenges, but they face manufacturing hurdles. Here’s how Vaxxas is trying to overcome them. Merck (NYSE:MRK) and Vaxxas announced earlier this year that the pharmaceutical giant was using Vaxxas’ High Density Microarray Patch (HD-MAP) platform as a delivery platform for a vaccine candidate. Vaxxas did not disclose what […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: coronavirus, COVID-19, Harro Höfliger, Merck, Vaxxas

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 8
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS